XCOPRI 150 MG TABLET
FDA nonproprietary name: cenobamate
For 30 tablets
Pharmacies pay
$1,195.89 filed
30 × $39.8629 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$1,152.82 filed
30 × $38.42747 per EA, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
0.96× estimated
Medicare paid about what pharmacies pay.
Part D averages every strength and form sold under “Xcopri” / “Cenobamate” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$1,380.27 estimated
$1,195.89 + $179.38 (15%) + $5.00 fee per fill = $1,380.27
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
XCOPRI 150 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as cenobamate, under the trade name “Xcopri”.
FDA gives its dosage form as tablet, film coated and its route as oral.
The labeler, the company named on the label, is SK Life Science, Inc.
FDA lists no Established Pharmacologic Class for it.
The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 71699-0150-30.
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $1,195.89 for 30 tablets (30 × $39.8629 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.
What NADAC measures · Why 30 tablets · NADAC explanation codes
The NDC
- 71699-0150-30 · SK Life Science, Inc. · $39.8629 per EA · eff. 2026-09-23 filed
Other strengths, forms and brands
9 other products in the NADAC file share the FDA nonproprietary name cenobamate with XCOPRI 150 MG TABLET.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| XCOPRI 12.5-25 MG TITRATION PK | $3.91043 per EA filed | $38.42747 per EA filed |
| XCOPRI 25 MG TABLET | $39.88192 per EA filed | $38.42747 per EA filed |
| XCOPRI 50 MG TABLET | $39.85674 per EA filed | $38.42747 per EA filed |
| XCOPRI 50-100 MG TITRATION PAK | $42.71457 per EA filed | $38.42747 per EA filed |
| XCOPRI 100 MG TABLET | $39.87152 per EA filed | $38.42747 per EA filed |
| XCOPRI 150 MG TABLET this page | $39.8629 per EA filed | $38.42747 per EA filed |
| XCOPRI 150-200 MG TITRATION PK | $42.9098 per EA filed | $38.42747 per EA filed |
| XCOPRI 200 MG TABLET | $39.8775 per EA filed | $38.42747 per EA filed |
| XCOPRI 250 MG DAILY DOSE PACK | $21.36879 per EA filed | $38.42747 per EA filed |
| XCOPRI 350 MG DAILY DOSE PACK | $42.69935 per EA filed | $38.42747 per EA filed |
Part D is one average per brand and generic name, over every strength and form.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
What Medicare paid
Medicare Part D paid $1,152.82 for 30 tablets, at an average of $38.42747 per EA in 2024 (2024-01-01 to 2024-12-31) for “Xcopri” and “Cenobamate”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 117,028 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for XCOPRI 150 MG TABLET labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Xcopri / Cenobamate: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.